# BESCHWERDEKAMMERN PATENTAMTS

# BOARDS OF APPEAL OF DES EUROPÄISCHEN THE EUROPEAN PATENT OFFICE

CHAMBRES DE RECOURS DE L'OFFICE EUROPÉEN DES BREVETS

### Internal distribution code:

- (A) [ ] Publication in OJ
- (B) [ ] To Chairmen and Members
- (C) [ ] To Chairmen
- (D) [X] No distribution

# Datasheet for the decision of 3 May 2021

Case Number: T 1375/19 - 3.3.07

Application Number: 13178507.3

Publication Number: 2679217

A61K9/00, A61K47/10, A61K47/26, IPC:

A61K47/32, A61K38/48

Language of the proceedings: ΕN

### Title of invention:

Non-protein stabilized clostridial toxin pharmaceutical compositions

# Patent Proprietor:

ALLERGAN, INC.

### Opponent:

IPSEN PHARMA S.A.S.

### Headword:

Stabilized clostridial toxin/ALLERGAN

### Relevant legal provisions:

EPC Art. 113(2)

### Keyword:

Basis of decision - text or agreement to text withdrawn by patent proprietor - patent revoked

# Decisions cited:

T 0073/84



# Beschwerdekammern Boards of Appeal Chambres de recours

Boards of Appeal of the European Patent Office Richard-Reitzner-Allee 8 85540 Haar GERMANY

Tel. +49 (0)89 2399-0 Fax +49 (0)89 2399-4465

Case Number: T 1375/19 - 3.3.07

DECISION
of Technical Board of Appeal 3.3.07
of 3 May 2021

Appellant: ALLERGAN, INC.

(Patent Proprietor) 2525 Dupont Drive
Irvine, CA 92612 (US)

Representative: Hoffmann Eitle

Patent- und Rechtsanwälte PartmbB

Arabellastraße 30 81925 München (DE)

Appellant: IPSEN PHARMA S.A.S. (Opponent) 65, Quai Georges Gorse

92100 Boulogne-Billancourt (FR)

Representative: Plasseraud IP

66, rue de la Chaussée d'Antin 75440 Paris Cedex 09 (FR)

Decision under appeal: Interlocutory decision of the Opposition

Division of the European Patent Office posted on 12 March 2019 concerning maintenance of the European Patent No. 2679217 in amended form.

### Composition of the Board:

Chairman A. Usuelli Members: M. Steendijk P. Schmitz - 1 - T 1375/19

# Summary of Facts and Submissions

- I. In its interlocutory decision posted on 12 March 2019, the opposition division considered that European patent No. 2 679 217 (hereinafter: the patent) in an amended form met the requirements of the EPC.
- II. The proprietor (hereinafter: appellant-patent proprietor) and the opponent (hereinafter: appellant-opponent) filed appeals against this decision.

The appellant-patent proprietor requested that the decision under appeal be set aside and that the patent be maintained as granted or, subsidiarily, that the patent be maintained on the basis of one of the auxiliary requests 1-7 as filed with the grounds of appeal.

The appellant-opponent requested that the decision under appeal be set aside and that the patent be revoked in its entirety.

III. With a letter dated 19 April 2021 the appellant-patent proprietor withdrew its appeal and requested 50% reimbursement of the appeal fee in line with Rule 103(3)a) EPC.

The appellant-patent proprietor was informed of the refund order in a communication dated 28 April 2021.

IV. In a letter dated 21 April 2021 the appellant-patent proprietor declared that it no longer approved the text in which the patent was granted, that it withdrew all auxiliary requests and that it did not intend to submit

- 2 - T 1375/19

further amendments, observing that the patent is to be revoked.

# Reasons for the Decision

1. The appellant-patent proprietor has indicated that it no longer agrees with the text of the patent as granted and that following the withdrawal of its auxiliary requests 1-7 it did not intend to provide any alternative claims. Pursuant to Article 113(2) EPC a patent can only be maintained on the basis of a text submitted or agreed to by the patent proprietor. In the absence of such agreed text the patent can only be revoked (cf decision T 0073/84 (OJ EPO 1985, 241)).

- 3 - T 1375/19

# Order

# For these reasons it is decided that:

- 1. The decision under appeal is set aside.
- 2. The patent is revoked.

The Registrar:

The Chairman:



B. Atienza Vivancos

A. Usuelli

Decision electronically authenticated